A smooth flat wire wrapped over a stainless steel core provides balanced performance. The Amplatz superstiff proximal shaft ensures ultimate pushability and control while the floppy distal shaft enables precise, less traumatic advancement. Smooth, rounded ends and PTFE coating ease passage.

• Used for temporarily facilitate drainage of urine from kidney to bladder by trained physician. • A full new line of ureteral stent with enhanced radiopacity for easier visualisation.

The Align® Retropubic/Suprapubic/Retropubic-Suprapubic (R/S/RS) Urethral Support System (Align® Urethral Support System) is a suburethral sling device intended for the treatment of female stress urinary incontinence. The system comprises stainless steel introducers and a polypropylene mesh sling implant encased in a protective sheath with green guide tubes at each end of the sheath. Connectors are attached to the distal ends of the guide tubes, and are designed to attach to the tip portion of the introducer needles. The device is terminally sterilized by ethylene oxide.

Agarose - Separation ≥ 500 bp

Our full line of adult silicone Foleys includes 2-way and 3-way designs with both 5/10ml and 30ml balloons.

The Microgel/Interlab G26 Acid Hemoglobins Electrophoresis method provides a new level of total automation on agarose gel. You simply pipette the hemolysates into the sample wells, put the gels in the holders, start the instrument and walk away! Synthesis of hemoglobin is under genetic control and the presence of abnormal hemoglobins is associated with functional, physical and morphological abnormalities of the red cells. Hemoglobins are composed of polypeptide chains of globin and iron protoporphyrin heme groups. Normal hemoglobins have similar structures with a molecular weight of about 67,000 daltons and consist of 2 pairs of globin chains each associated with one molecule of heme. Normal adult hemoglobins are HbA (98 percentage of total hemoglobin) and small amounts of HbA2 and HbF. Substitution of aminoacids in the polypeptide chains sequence leads to the formation of abnormal hemoglobin variants. At present over 600 structural hemoglobins variants are known: HbS, HbC, HbE, HbD, HbG, HbH, HbI, Hb Lepore, etc. Hemoglobinopathies are a group of diseases caused by the presence of abnormal hemoglobins. About 60 percentage of abnormal hemoglobins have a sufficiently altered charge distribution to be identified by electrophoresis. The variants most frequently observed are HbS and HbC. Concomitant presence of HbA and another variant (HbS, HbC, HbE, etc.) is referred to as heterozygous hemoglobinopathy AS, AC and AE respectively. The presence of only one single type of hemoglobin variant is called homozygous hemoglobinopathy, like HbS or HbC. These abnormal variants are genetically transmissible. Homozygous hemoglobinopathies may cause serious clinical effects. Acid hemoglobin electrophoresis on agarose allows confirmation of the presence of HbS or HbC already detected by Alkaline Hemoglobins electrophoresis.

These unique Acid Fast Control Slides simulate a clinical sputum smear with appropriate background material. Slides have two wells containing a positive and negative smear. Can be used with Kinyoun (Cat. No. 353), Ziehl-Neelsen or SDL’s new product AcriFluor or other fluorescent techniques.

23 inch x 35 inch (60cm x 90cm) Urological Drape, clear plastic, adhesive strip, circle aperture, neoprene finger cot, aperture size 2 inches (5,2cm)

64 inches (164cm) TUR Drape, absorbent prevention fabric, abdominal adhesive aperture, elastic aperture, neoprene finger cot, fluid collection pouch with filter and exit port; arm extension 60 inches (152cm), aperture 2 inches (6cm)

Cystoscopy Surgical Drape Pack, op tape, hand towels, leggings (pair), perineal aperture drape, back table cover

Our Mission Improve people’s health by delivering optimal access to high quality Biopharmaceuticals at competitive price. Our Vision To be a world leading provider of innovative Research & Therapeutic proteins About us Feldan Bio develops, manufactures and distributes high quality recombinant Biopharmaceuticals at competitive price. Over the years, Feldan Bio has developed one of the world's largest range of proteins including, E. coli, insect, and mammalian cell-derived recombinant proteins. Our extensive product line includes Cytokines, Growth Factors, Chemokines, Enzymes, Antibodies, Viral Antigens, Hormones, Toxins, Receptors and Feldan Bio’s proprietary developed technologies provide an edge over the competition due to lower production costs, high yields and production efficiencies. We thrive for quality, which is the essential factor in achieving a favourable position in the market place and the benefits associated with manufacturing top quality products. Every batch we produce is strictly tested to meet the requirements of clinical grade Biopharmaceuticals. Feldan Bio provides; Research Proteins to basic research, clinical research, and clinical diagnostic markets around the world with Recombinant Research Proteins for cancer, development, endocrinology, immunology, neuroscience, proteases, and stem cell research. Therapeutic Proteins that are the generic equivalent of brand Biopharmaceuticals that no longer enjoy patent protection. Feldan Bio provides a comprehensive range of top cGMP generic Therapeutic Proteins that are tailored to its customers' need. Full Technology Transfer: Feldan Bio offers Full Technology Transfer of its Technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis. Feldan Bio has customers in life science companies, universities and government institutions, hospitals and industry in 56 countries and offers excellent products and services in 7 countries.

PercSys is a medical device company focused on providing a suite of single-use tools to improve every type of kidney/ureteral stone treatment in every location within the urinary tract. The company’s goal is to make endourologic kidney stone procedures easier, less traumatic, and more effective therapeutically. PercSys currently offers two products for stone fragment containment and removal. The 7 and 10mm PercSys Accordion Stone Management Device is designed for ureteroscopic lithotripsy procedures and the 15mm Accordion CoAx Stone Control Device is optimized for percutaneous nephrolithotomy (PCNL) procedures.

Battery-driven vacuum system operates with a touch of a button.

Features various cylinder sizes and a simple two-handed pumping mechanism.

Although other treatments for ED (e.g. Viagra®, Injections and Penile implants) are widely used today, Vacuum Therapy is gaining increasing popularity by patients and their physicians because of the very positive associated benefits. In fact, Vacuum Therapy should be used as a daily exercise to prevent atrophy and to promote penile health. Evidence from leading urologists promotes the idea that this treatment improves penile health by restoring adequate blood flow and revitalizing vascular tissues.

Features • The No Scalpel Vasectomy Ring Clamp isolates and secures the vas deferens without penetrating the skin • The No Scalpel Vasectomy Hemostat pierces the scrotal sac to expose the vas deferens • The vas deferens is lifted out of the scrotum with the No Scalpel Vasectomy Hemostat and occluded • Gold finger rings for easy identification

Durable Stainless Steel 2 Year Warranty

Li Brand™ Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company. 3.0 mm and 4.0 mm ring diameter available. Simply indicate in order comments.

Non-Cantilevered, "Teardrop" Ringed Forceps. ("Wilson style fixation clamp") For vasectomy and other procedures. Ring ovoid approximately 6.0 mm in diameter.

Non-Cantilevered Ringed Forceps. ("fixation clamp") For vasectomy and other procedures. Ring diameter approximately 3.0 mm. Manufactured exclusively for AMI to exacting specifications by a German company.

Vasectomy Ringed Forceps

Li Brand Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company. 3.0 mm and 4.0 mm ring diameter available. Simply indicate in order comments.

Researchers at the University of Minnesota are closer to developing a simple urine test to identify smokers who are at high risk of developing lung cancer. Although the test is still years away, the hope is to spot high-risk people earlier when there is still time to prevent or treat the cancer, says Jian-Min Yuan, MD, associate professor of cancer epidemiology at the University.

LifeCycle Pharma A/S has announced the enrollment of the first patient in its Phase 3 clinical trial program for use of LCP-Tacro™ in the prevention of organ rejection in stable kidney transplant patients. The clinical trial protocol has been reviewed by FDA, and LCP expects to enroll approximately 300 stable kidney transplant patients in the program. The study will be conducted at approximately 50 sites in U.S. and Europe and the clinical trial results are expected by second half of 2010.

USHIFU has announced the establishment of India HIFU and the launch of Sonablate(R) HIFU services in Hyderabad, India at Dr. Ramayya’s Pramila Hospital for the treatment of prostate disease. The introduction of the Sonablate(R)500 and the HIFU technology for the treatment of prostate cancer marks a major milestone in the practice of urology in the Indian sub-continent. As the population is aging with a healthy lifestyle it is imperative that patients with prostate cancer are offered a viable alternative to the existing therapy options of surgery and radiotherapy.

According to Millennium Research Group’s (MRG’s) European Markets for Urological Devices 2009 report, the prostate cancer device market-comprising brachytherapy seeds, cryotherapy, and high-intensity focused ultrasound (HIFU) devices-will be driven by earlier detection of prostate cancer due to an increase in screening over the next five years. Screening allows for early detection of cancer, enabling treatment at a curable stage that can be facilitated through minimally invasive devices, such as those required for brachytherapy, cryotherapy, and HIFU procedures.

UroToday.com - Overactive bladder is a key battleground for the pharmaceutical industry and an area of considerable significance to health delivery systems. Given the substantial effects on quality of life, patients are understandably keen for therapeutic strategies which are effective without the significant side effects of anticholinergic drugs. Finally, clinicians have to deal with refractory urinary urgency, which constitutes a significant burden. Published evidence appears to set a confident and positive outlook; a range of effective anticholinergic drugs is available, whilst botulinum toxin is perceived to mop up those who remain bothered despite conservative and medical management.

Cardium Therapeutics and its operating unit InnerCool Therapies, Inc., has developed a pelvic cooling catheter system called UroCool(TM). The product is designed to induce localized cooling during surgery for prostate cancer (radical prostatectomy). The new technology is being applied in collaboration with renowned prostate surgeon, Thomas E. The UroCool(TM) catheter is placed within the rectal cavity adjacent to the prostate during surgery. It is used in conjunction with InnerCool’s Celsius Control Console which circulates cold saline in a closed loop within the catheter to allow for localized cooling.

Questcor Pharmaceuticals, Inc. has announced that it will be considering its principal product H.P. Acthar for use in a new area – nephrotic syndrome. In this condition, there is excessive spilling of protein into the urine from the kidneys of the patient. Acthar is specifically indicated to deal with this condition (proteinuria). Questcor is in discussions with nephrologists about the possible therapeutic application of Acthar. A broader indication for the product is expected in future.

The U.S. Food and Drug Administration has approved Watson Laboratories’ Rapaflo (silodosin) capsules for the treatment of symptoms of benign prostatic hyperplasia (BPH). Having high affinity for α-receptors concentrated in the prostate, the blocker binds them to smoothen muscles in the tissues. This relaxes them, improving flow of urine and reducing symptoms of BPH such as retrograde ejaculation, dizziness etc.

A recent study conducted by the Department of Urogynaecology at King’s College Hospital in London to measure the efficacy of solifenacin in treating patients suffering from overactive bladders has concluded that the drug shows positive results in as little time as three days. A 70 per cent reduction was reported in urgency in patients receiving solifenacin as compared to 50 per cent for those taking the placebo.

According to the findings of a clinical study conducted by researchers from Umea University in Sweden, adult male patients of locally advanced prostate cancer can gain from addition of radiation to androgen deprivation therapy. The study found that the group which received radiotherapy along with hormone therapy had greater survival rate. The risk of death from prostate cancer was cut by half.